Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology

Author:

Schaeffer Edward M.1,Srinivas Sandy2,Adra Nabil3,An Yi4,Barocas Daniel5,Bitting Rhonda6,Bryce Alan7,Chapin Brian8,Cheng Heather H.9,D’Amico Anthony Victor10,Desai Neil11,Dorff Tanya12,Eastham James A.13,Farrington Thomas A.14,Gao Xin10,Gupta Shilpa15,Guzzo Thomas16,Ippolito Joseph E.17,Kuettel Michael R.18,Lang Joshua M.19,Lotan Tamara20,McKay Rana R.21,Morgan Todd22,Netto George23,Pow-Sang Julio M.24,Reiter Robert25,Roach Mack26,Robin Tyler27,Rosenfeld Stan28,Shabsigh Ahmad29,Spratt Daniel15,Teply Benjamin A.30,Tward Jonathan31,Valicenti Richard32,Wong Jessica Karen33,Shead Dorothy A.34,Snedeker Jenna34,Freedman-Cass Deborah A.34

Affiliation:

1. Robert H. Lurie Comprehensive Cancer Center of Northwestern University

2. Stanford Cancer Institute

3. Indiana University Melvin and Bren Simon Comprehensive Cancer Center

4. Yale Cancer Center/Smilow Cancer Hospital

5. Vanderbilt-Ingram Cancer Center

6. Duke Cancer Institute

7. Mayo Clinic Comprehensive Cancer Center

8. The University of Texas MD Anderson Cancer Center

9. Fred Hutchinson Cancer Center

10. Dana-Farber/Brigham and Women’s Cancer Center | Mass General Cancer Center

11. UT Southwestern Simmons Comprehensive Cancer Center

12. City of Hope National Cancer Center

13. Memorial Sloan Kettering Cancer Center

14. Prostate Health Education Network (PHEN)

15. Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

16. Abramson Cancer Center at The University of Pennsylvania

17. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

18. Roswell Park Comprehensive Cancer Center

19. University of Wisconsin Carbone Cancer Center

20. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

21. UC San Diego Moores Cancer Center

22. University of Michigan Rogel Cancer Center

23. O’Neal Comprehensive Cancer Center at UAB

24. Moffitt Cancer Center

25. UCLA Jonsson Comprehensive Cancer Center

26. UCSF Helen Diller Family Comprehensive Cancer Center

27. University of Colorado Cancer Center

28. University of California San Francisco, Patient Services Committee Chair

29. The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

30. Fred & Pamela Buffett Cancer Center

31. Huntsman Cancer Institute at the University of Utah

32. UC Davis Comprehensive Cancer Center

33. Fox Chase Cancer Center

34. National Comprehensive Cancer Network

Abstract

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment intensification is strongly recommended for patients with metastatic castration-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the addition of certain secondary hormone therapies depending on prostate-specific antigen doubling time. In the mCRPC setting, ADT is continued with the sequential addition of certain secondary hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, the presence or absence of visceral disease, symptoms, and potential side effects.

Publisher

Harborside Press, LLC

Subject

Oncology

Reference165 articles.

1. Cancer statistics, 2023;Siegel RL,2023

2. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement;Moyer VA,2012

3. Effect of the USPSTF grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States;Barocas DA,2015

4. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening;Drazer MW,2015

5. Recent trends in PSA testing and prostate cancer incidence: a look at context;Etzioni R,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3